Industrial Automation Magazine India

Empowering Regenerative Medicine: 3A-GTP Technology ushers in a new epoch

Published on : Monday 31-07-2023

Pioneering Green Energy Solutions: Dr.Signal Biotech and J&V Energys promising alliance.

Taipei, July 2023 – At the 2022 Healthcare Expo Taiwan, Dr.Signal Biotech showcased the remarkable 3A-GTP technology, succeeding a significant breakthrough. This technology accelerates the popularisation of stem cell therapy, enabling large-scale production of stem cells, and providing the unique capability of quantifying and standardising cell processing for cell therapy CDMO service in Taiwan, paving the way for a new era in regenerative medicine. At the 2023 BioAsia Expo, Dr.Signal Biotech collaborated with J&V Energy to unveil their exclusive positive to negative carbon emission conversion technology, offering a revolutionary solution for global governments and businesses to overcome carbon anxiety. With the theme Green Power • Golden Bio, it heralds the arrival of Taiwans golden age in the biotech industry, leading the way for the blossoming of both the biotech and green energy sectors.

According to Frost & Sullivan market research, the global CDMO market rapidly rose from $35.3 billion in 2016 to $55.5 billion in 2020, with an impressive compound annual growth rate (CAGR) of 12%, far surpassing the pharmaceutical markets 3% during the same period. Looking ahead, it is estimated that the market size will reach $106.6 billion by 2025.

Taiwans biotech industry has achieved remarkable results through long-term efforts. As reported recently, the revenue of Taiwans biotech industry has been steadily climbing from NT$421.5 billion in 2015 to NT$591.3 billion in 2020. Even more promising is that it surpassed the trillion-dollar market cap in 2015 and again in 2020, indicating the potential for the biotech industry to become a two-trillion-dollar sector. The key to achieving this goal lies in the leading role of CDMO. Moreover, this immense opportunity signals that the entire CDMO business model will become a future trend, bringing unprecedented development prospects for Taiwans biotech industry.

Dr.Signal Biotech is firmly advancing intelligent automation in cell processing, utilising a unique combination of Artificial Intelligence (AI), Augmented Reality (AR), and Automation (Auto), while incorporating Good Tissue Practice (GTP) guidelines to accomplish the goal of digital cell processing. Chairman of Dr.Signal Biotech, Hsin-Wu Mi, pointed out that the groundbreaking 3A-GTP technology led by the company has outperformed traditional GTP laboratories with astonishing efficiency. Data shows that 3A-GTP technology boasts a 10-fold increase in cell production per person, 6-fold higher average productivity per unit area, and a cell processing cost per 0.1billion cells only 1/10 of that in manual cell culture.

Simultaneously, tens of thousands of digital parameters related to cell processing are collected daily, providing a basis for deep learning in the AI intelligence system. With seamless integration of software and hardware in the future, the comprehensive efficiency of 3A-GTP technology is projected to reach hundreds of times that of old-style GTP laboratories, establishing Dr.Signal Biotechs competitive edge in the cell therapy CDMO service.